Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Eisai Boosts Inventory For Possible Flu Pandemic

This article was originally published in PharmAsia News

Executive Summary

As a measure to ward off a possible flu pandemic, Eisai maintains three month's worth of drug inventories in three Japanese factories as well as factories in the U.S., Taiwan, China and Indonesia. Eisai also has secured two month's worth of inventories in drug materials, and has initiated a multiple-supplier system. Eisai sells products to over 70 countries and revenue from overseas markets accounts for 60 percent of its sales. President Haruo Naito said that even if stocking inventory costs more, it is necessary to ensure uninterrupted supply. Other companies such as Takeda are also considering taking similar inventory measures and Pfizer has made a manual according to different stages of a pandemic, and set up a system that is able to import drugs from China and the U.S. in a crisis. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068114

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel